THE SCOPE

Vol. 26, No. 3, Summer 2008

STUDENT AND MENTORS SPEND TIME ON ALCATRAZ ISLAND

Fifty STP students, guests, and mentors sailed to Alcatraz on Tuesday afternoon of the San Francisco Annual Meeting. The outing was organized by the Student Interaction Subcommittee of the Career Outreach Committee.

STP 27TH ANNUAL MEETING IN SAN FRANCISCO DRAWS RECORD ATTENDANCE

The San Francisco Hyatt Regency served as an ideal venue in June when nearly 700 scientists, exhibitors, and guests attended the 27th STP Annual Meeting, Systems Pathology: Evaluating Complex Pathological Systems from Molecule to Morphology. This was a record turnout for the annual meeting. Thanks are extended to Scientific Chair, **Eugenia Floyd** (Pfizer); Symposium Committee Chair, **Andy Fix** (Procter and Gamble); Executive Committee Liaison, **Jerry Ward** (Consultant); CE Program Chair, **Kathleen Funk** (EPL, Inc.); and CE Committee Chair, **Brian Berridge** (GlaxoSmithKline) and all the speakers and session chairs for their time and effort in organizing an exceptional program.

Pathology Potpourri, was the theme of the premeeting interactive NTP Satellite Symposium, which was organized by **Susan Elmore** (NIEHS). More than 200 people participated in the full day free course. Speakers were **Amy Brix** (EPL, Inc.); **Ron Herbert** (NIEHS); Jerry Ward (Consultant); **Dave Malarkey** (NIEHS); **Gordon Flake** (NIEHS); **Todd Painter** (ILS, Inc); **Akiyoshi Nishikawa** and **Takanori Harada** (NIEHS/The Institute of Environmental Toxicology, Japan); **Bob Maronpot** (Maronpot Consulting, LLC.)

continued on page 6

INSIDE

PRESIDENT'S REPORT

Ricardo Ochoa

Colleagues:

As summer 2008 comes to a close, our future landscape is replete with challenges and opportunities both at home and overseas. The United States is in the throes of a political campaign for selecting the next president and the nation's strategic direction for the next four years. We are still at war in Iraq, which has cost the U.S. and other countries much in capital (both economic and political) and human lives; the country is still reeling from the direct terrorist attacks of September 11, 2001, and is determined that they will not be repeated. Globally, there is a challenging economic environment that has produced a downturn in financial markets around the world. The U.S. and many other countries are facing a renewal of inflation at levels not seen in over a decade. The dollar has lost value, increasing the trade deficit, and the imbalance in the U.S.A budget. However, there are signs that the factors evoking these problems are about to change. The electorate in the U.S.A will have an opportunity to evaluate the qualifications of the future president, to select between significantly diverging political approaches to the resolution of the internal and international challenges. Similarly, the war has begun to show some signs that there may be a realistic exit strategy in the foreseeable future. At the end of summer 2008, and thanks to the response of an American public which decided that there was a need to conserve energy as well as the slight increase in the value of the dollar, the cost of gasoline has stopped its steep climb. Sustainability of these gains will certainly help the economy.

This framework of national and international issues is important to the Society of Toxicologic Pathology. Our organization and specifically its leadership need to keep an eye on the macroeconomic trends

continued on page 3

Welcome! NEW MEMBERS

Fiorella Belpoggi.....European Ramazzini Foundation

Kelli Boyd.....St. Jude Children's Research Hospital

Eberhard Buse.....Covance Laboratories GmbH

Jennifer Chilton.....Charles River Preclinical Services Nevada

Joshua Decker.....Abbott Laboratories

Majid Ghoddusi.....Comparative Biosciences Inc.

Amy Guo.....BioDuro

Paula Katavolos.....Schering-Plough Research Institute

Klaus Krauser.....Arena Pharmaceuticals Inc.

Byoung-Seok Lee.....Korea Institute of Toxicology(KIT)

Gloria Marselas.....U.S. Army

Jagannatha Mysore.....Pfizer Inc

Thomas Rosol.....Ohio State University

Minoru Sasaki.....Banyu Pharmaceutical Co. Ltd.

Quincey Simmons.....Vertex Pharmaceuticals Inc

Matthew Smith.....Bristol-Myers Squibb

Jacqueline Tarrant.....Genentech

Hui Wang.....Medicilon/MPI Preclinical Research (Shanghai) LLC.

Karen Wang.....Bridge Laboratories

Yohei Miyamoto.....Toxicology and Pharmacokinetics Laboratories Toray Industries Inc.

Pushkar Pal.....Institute of Agriculture and Animal Sciences Nepal

Janelle Renschler.....North Carolina State University

Jonathan Sparkes.....Instem-LSS

Xueqing Wang.....ITR

Seonock Woo.....University of Cailfornia-Berkeley

Kara Corps.....College of Veterinary Medicine Michigan State University

Melanie Greeley.....University of California Davis

Shankang Ma.....University of Louisville

Sunish Mohanan.....Wake Forest University School of Medicine

Alicia Olivier.....Iowa State University College of Veterinary Medicine

Melissa Sanchez.....University of Pennsylvania

Brent Walling.....University of Illinois

Janet Beeler-Marfisi.....University of Guelph Ontario Veterinary College

Tapan Bhavsar.....St. John's University

Tania Mendes De Carvalho....Molecular Pathobiology Research Centre (CIPM)

STP Newsletter **Society of Toxicologic Pathology**

Editor
Jim Crissman
(989) 631-2790 (MI)
jcrissman@charter.net

Newsletter Committee
Alok Sharma
(608) 242-2712 x2856 (WI)
alok.sharma@covance.com

Amrith Nair
(215) 652-3657 (PA)
amrithraj_nair@merck.com

Bindhu Michael
(215) 652-3662 (PA)
bindhu_michael@merck.com

Frank Simutis
(812) 429-8113 (IN)
frank.simutis@bms.com

Brad Bolon
(303) 772-7664
Brad@gempath.net

Randy White
(812) 429-8341 (IN)
randy.white@bms.com

Sue Pitsch, Executive Director
(703) 438–7508 (VA)

STP Headquarters
1821 Michael Faraday Drive, Suite 300
Reston, VA 20190-5348
www.toxpath.org
stp@toxpath.org

Send newsletter material to STP Headquarters at the address above, or by Fax to (703) 438–3113.

The Society of Toxicologic Pathology Newsletter (ISSN #10761535) is published 4 times a year by the Society of Toxicologic Pathology, c/o AIM, 1821 Michael Faraday Dr., Suite 300, Reston, VA 20190-5348. Membership dues include $5.00 for the cost of publication. Send address changes to STP Newsletter, Society of Toxicologic Pathology, 1821 Michael Faraday Dr., Suite 300, Reston, VA 20190-5348.

THEME OF 2009 ANNUAL SYMPOSIUM IN WASHINGTON, D.C. IS CANCER

The 2009 Annual Symposium will take place June 21–25, 2009 at the Wardman Park Marriott, Washington, D.C. The 2009 STP Symposium will cover the broad topic of Cancer in animals and humans. Cancer is a major cause of death in humans throughout the world. Cancer involves all organ systems and has many etiologies including chemicals, viruses and irradiation but also has many important modifying factors such as genetics and diet. Cancer is the endpoint of a multistage process which begins as focal hyperplastic lesions and progresses, often through benign neoplasia, to malignant neoplasia. Toxicologic pathologists are often involved in studies involving tumors as an endpoint, including basic cancer research, studies with genetically engineered mice, and toxicology and carcinogenicity assays for safety assessment of chemicals. This symposium will cover various aspects of cancer: human cancer, cancer biology, mechanisms of carcinogenesis, regulation of carcinogens, use of genetically engineered mice for carcinogenesis bioassays, and tumor pathology. Continuing education courses on cancer drug development and other subjects with the Saturday NTP session, which will emphasize tumor pathology, will round out the Symposium on Cancer.

Preliminary meeting information, hotel reservations, and registration will be available in early September at **www.toxpath.org/AM2009**.

President's Report

continued from page 1

to help our membership direct its efforts toward preparation for the future, both as individuals and as a community. The pharmaceutical industry is still facing tremendous challenges. There are increasing calls for cost control measures, which are expected to become more strident in the future, with the baby boom generation entering Medicare and having to pay for increasing numbers of medications as they get older. Legislators and administrators will press for control of expenditures on government-funded medical costs, and the cost of medications have proven to be an easy target. This in turn will continue to press pharmaceutical companies to further control the spiraling costs of their own research and development processes, forcing them to reduce personnel, and focus their development more sharply. Recently there has been a tremendous move from pharmaceutical companies toward decreasing their fixed costs by increasing the outsourcing, and reducing the amount of toxicology work that is performed in their facilities. This may represent increasing momentum to consider regulatory toxicology as a service to be contracted. Contract Research Organizations (CROs) have been increasing their capacity, and now many of the CROs have Toxicologic Pathology teams on staff that rival the size and quality of their counterparts at major pharmaceutical companies of the past.

Pressures are also increasing for making investments in and using labor from countries where labor is less expensive. This will have the effect of increasing pressure for recognition of the training and expertise of those colleagues, as well as for playing a role in the assurance of the quality of their product.

As the oldest and largest organization of its type, the Society of Toxicologic Pathology has an opportunity and a responsibility to play a leading role in the maintenance and improvement of scientific expertise in the field. The STP is stepping up to these responsibilities in several ways:

We have created significant partnerships with other sister organizations, such as the agreement that *Toxicologic Pathology* will be the official journal of both the STP and the British Society of Toxicologic Pathologists (BSTP). Our new Editor-in-Chief, **John Foster**, who is a member of both societies, is doing a magnificent job of managing the editorial office. The Executive Committee of STP has agreed to increase the number of issues of our Journal by approving the creation of one or several special issues every year. The special issues will be subject matter focused and will constitute a great learning tool and reference resource for our membership and for all other professionals interested in toxicologic pathology.

The STP has re-engaged with the International Federation of Societies of Toxicologic Pathology (IFSTP), so that we as a Society will be supporting their activities, and making sure that our membership is represented appropriately in their strategy and leadership. As such, our past Secretary-Treasurer, **Jeff Engelhardt**, is President-elect of IFSTP, and **Brad Bolon** is the STP liaison to their Executive Committee. Brad has been working with the leadership of IFSTP to develop an internationally acceptable policy regarding the potential criteria for global recognition of Toxicologic Pathologists. The current draft of the most recent IFSTP position paper on this topic can be accessed at **https://www.toxpath.org/membersonly/pos.asp**. Please send your comments to **Brad@gempath.net** by Sept. 2, if you have not already done so, so that your opinions can be communicated to the IFSTP and other STPs later this year.

We continue to support efforts in other countries to form their own STPs and to have training programs for their scientists in the field. In particular, we have supported activities in China and India during the last year by contributing both expert speakers and some financial support.

The participation of international colleagues at our annual symposium continues to increase, and overall attendance continues to set new records. The STP is certainly considered by many an important authority on the field of Toxicologic Pathology. Next year, we are due back in Washington, DC. This meeting is part of our resolution to have the meeting in the vicinity of the U.S.A capital on a regular basis in order to facilitate participation by our colleagues working in governmental agencies. Their contributions are thus recognized, and hopefully they will respond as in the past by participating in our meeting. The EC has approved a suggestion from the Symposium Committee to offer a full day (special morning and afternoon sessions) directed to our colleagues who work for the government. They will not be asked to pay registration for this day if they register in advance, and the program is being designed for maximum relevance to them. **Jerry Ward** and **Kathleen Funk**, Scientific Co-chairs; **Andy Fix**, Symposium Committee Chair; and **Brian Berridge**, Continuing Education Committee are working to make the 2009 Washington meeting even more of a success than our recent ones. Details and registration portals for this event will be available at **www.toxpath.org** in early September.

There are multiple other activities that the Executive Committee has acted on, and that are too numerous to point out in this open letter. The EC feeds and grows with the input of the membership, and many of our best ideas come from our members. So, I am asking you to make sure that you provide this input to the Executive Committee **(http://www.toxpath.org/membersonly/officers.asp)** and that you stay engaged in the running of this organization at this time of great change and magnificent opportunity.



Ricardo Ochoa

STP ANNUAL MEMBERSHIP DUES WILL INCREASE IN 2009

The STP has a long tradition of thoughtful stewardship in employing funds obtained from its members. This tradition has allowed STP to maintain essential member services with infrequent increases in annual dues. STP annual dues for full members were last raised in 2005. A modest increase in dues beginning in 2009 is necessary to help the STP pay for enhanced services to members, including preparing the INHAND microscopic nomenclature harmonization guides (to be published in *Toxicologic Pathology*), increased student travel awards and other forms of student outreach, career development seminars at the annual meeting, enhancements to the Web site, additional special supplements for *Toxicologic Pathology*, and continued STP participation in the International Federation of Societies of Toxicologic Pathology (IFSTP).

Accordingly, in 2009 STP annual membership dues will be:

- Full Members and Associate Members: $225 ($20 or ~10% increase).
- Student Members (with printed Journal): $65.
- Student Members (electronic access to Journal and Web site, but no printed Journal): $30 (no increase for members in this class).

Please address any questions or comments to STP Secretary-Treasurer Dan Morton **dan.g.morton@pfizer.com**) or to any STP Executive Committee member.

PLEASE UPDATE DEMOGRAPHIC INFORMATION FOR MEMBERSHIP DIRECTORY

Can be done easily when you pay dues on-line

The STP Membership Directory has a very useful search feature that can locate colleagues with one or multiple specific areas of professional interest (see screen shot below). This is in addition to the search by name, location or company functions. In order for this function to be most effective, everyone is asked to update their demographic information when you pay your dues on-line in September. (You will be prompted for this information if you pay your dues on-line.) You can select multiple options in the dropdown menu lists by holding down the CTRL key on a PC or the Open Apple key on a Mac. The STP database and Membership Directory will automatically be updated with any changes or additions you make.

You can also update your information by selecting "Update Member Info" from the left menu bar on the homepage at any time.



MEMBER RENEWAL NOTICE

Membership renewal notices will be e-mailed to all members in early September. Members are encouraged to use the on-line renewal option for speed and convenience, although a downloadable form will also be available on-line.

As in previous years, payment is due by December 1. It is important to renew by the deadline to ensure that your *Toxicologic Pathology* journal subscription continues without interruption. Should you have any questions regarding your membership, please contact the STP headquarters at stp@toxpath.org or (703) 438-7508.

STP MEMBERSHIP 2003–2008



NEW TEST CASES WANTED FOR "WHAT'S YOUR DIAGNOSIS" PAGE ON STP WEB SITE

Do you have an interesting slide you would like to share? You are encouraged to submit a case for posting on the Web site that so others can review and guess the answer. The "What's your Diagnosis" page can be accessed by selecting this option from the left menu bar at **www.toxpath.org.**

To Submit a New Case

This can be submitted to **stp@toxpath.org** and the STP web staff will upload images and text for you.

Please include signalment text (Species, Breed, Strain, Sex, Age, Use of animal this case was taken from) and items 1–8 below in the body of an e-mail or in a word doc. Images can also be e-mailed. Ideal size is 800 x 600 pixels. Staff can resize if necessary.

In the Message textbox please include:

1. Submitter's Name
2. Source Institution
3. Image Legend(s) describing for the uninitiated, what does each image show?
4. Morphologic Diagnosis for case and/or each image, if different.
5. Etiology: (Chemical Class, Therapeutic Class, Genetic Factors)
6. Condition, if different from morphologic diagnosis.
7. Background Discussion (a couple paragraphs is ideal)
8. References (up to 3)



DRAFT IFSTP WHITE PAPER ON GLOBAL RECOGNITION OF TOXICOLOGIC PATHOLOGISTS

The 21st century will see the rapid growth of global integration in all fields, including the practice of toxicologic pathology. Individuals and professional groups worldwide can either follow these trends or lead them. Accordingly, the Society of Toxicologic Pathology has renewed its participation in the International Federation of STPs (IFSTP) so that STP members may have a leading voice in guiding global initiatives that will affect the conduct of toxicologic pathology in coming decades.

One concrete result of this renewed STP/IFSTP relationship has been the preparation of an opinion paper regarding the potential need for providing global recognition of well-qualified toxicologic pathologists. This piece will be published in *Toxicologic Pathology* in a forthcoming issue and will outline possible means/methods (education, examination, credential review, peer review) by which a capable practitioner might be identified.

Relatively few STP members provided comments during the discussion period for this prior paper. Now you have a new opportunity to weigh in. A follow-up manuscript that describes a prospective global means for recognizing a qualified toxicologic pathologist has been drafted and is now being circulated for comments to the members of the various STPs which make up the IFSTP. This means you! Please take a few moments to reflect on the major questions raised in this new opinion piece: do we need a global forum for recognizing qualified toxicologic pathologists, and if so will this proposed scheme get the job done?

The draft paper may be accessed on the STP Web site using this link: **https://www.toxpath.org/membersonly/pos.asp**. I invite you to provide thoughtful comments or suggestions on this critical topic. Please send your thoughts to either **Brad Bolon** (STP Councilor and STP Representative to IFSTP) at **brad@gempath.net** or Sue Pitsch (STP Executive Director) at **spitsch@toxpath.org**. Responses should be sent by September 4 to ensure full consideration.

STP 27th Annual Meeting in San Francisco Draws Record Attendance

continued from page 1

Three Continuing Education courses were held on Sunday: Drug-Induced Phospholipidosis, was co-chaired by: **Linda Chatman** (Pfizer, Inc.); **Mark Cartwright**, (Schering-Plough Research Institute); and **Diann Weddle** (Abbott Laboratories, Inc.). Introduction to Bioinformatics for Pathologists was chaired by B**ruce Car** (Bristol-Myers Squibb Company). Toxicogenomics for Pathologists, was offered as a hands-on all-day course and chaired by **Kevin Morgan** and **Christopher Thompson** (sanofi-aventis).

Effective Communication for the Toxicologic Pathologist, was offered by the Career Outreach and Continuing Education Committees. This free workshop was co-chaired by **Eric Schultze** (Eli Lilly and Company) and **Brian Berridge** (GlaxoSmithKline). **Sabine Francke-Carroll** (U.S. FDA) discussed Regulatory Interactions and **John Vahle** (Eli Lilly and Company) spoke on Communicating Pathology Data to Non-pathologists. **Brad Bolon**, **Jerrold Ward**, and **John Foster** discussed Writing Skills for the *Toxicologic Pathologist*. The Career Outreach Committee also offered a lunchtime panel discussion, Career Paths Taken Are Not Always Straight, chaired by **Donna Dambach** (Genentech) and **Jack Harkema** (Michigan State University). **Peter Mann** (EPL, Inc.), **Bob Dunstan** (Biogen Idec, Inc.), **Curtis Colleton** (Bristol-Myers Squibb Co.), **Jack Harkema**, and **Donna Dambach** participated on the panel.

The Sunday evening Welcome Reception kicked off the opening of the Exhibit Hall, which featured nearly 40 booths with products and services relating to toxicologic pathology.

On Monday morning, **Dr. David J. Galas**, head of the life sciences programs at the Battelle Memorial Institute, and a faculty member at the Institute of Systems Biology in Seattle, gave the Keynote Address titled Accelerated Innovation in Drug Development and Environmental Protection from Application of Novel Technologies and Systems Biology. Chairs for each of the six half-day scientific sessions organized experts on their topic area. Systemic Pathobiological Pathways and Processes was co-chaired by **Dana Walker** (Bristol-Myers Squibb Company), and **Hajime Hiraragi** (Genentech.) Pathological Interactions of Major Organ Systems and Tissues was co-chaired by **Samuel Cohen** (University of Nebraska Medical Center) and **Thomas P. Brown** (Pfizer Global Research). Whole Animal Responses to Perturbations: Examples co-chairs: **Frances Clemo**, (Pfizer Inc.) and **Calvert Louden**, (AstraZeneca). Integrating Tissue Pathology with Systems Biology Data co-chairs: **Yvonne Dragan** (AstraZenec) and **Myrtle Davis** (Eli Lilly Research Laboratories). *In Vitro* Methods in Systems Biology Research co-chairs: **Donna Dambach** (Genentech) and **Katrina Waters** (Pacific Northwest National Laboratory). Evaluating Animal Responses to Combination Challenges co-chairs: **Douglas C. Wolf** (U.S. EPA) and **Prashant Nambiar** (Genzyme Corporation).

Posters

Ninety-nine poster abstracts were presented in the Exhibit Hall during exhibit hours on Monday, Tuesday, and Wednesday. **Hajime Hiraragi** served as Poster Chair and **Curtis Colleton**, (Bristel Myers Squibb Co.) **Thomas Brown** (Pfizer, Inc.) and **Calvert Louden** (AstraZeneca) served on the Poster Review Committee. **Hajime Hiraragi** and **Sarah Tannehill-Gregg**, reviewed the Student Travel abstracts and **Sarah Tannehill-Gregg, Donna Dambach**, **Suzanne Botts**, and **Thomas Brown** were the Young Investigator Award Judges.

The topic of the Monday evening Town Hall meeting was "Use of Historical Control Data in Carcinogenicity Studies." Members of the Scientific and Regulatory Policy Committee Working Group, chaired by **Charlotte Keenan** (GlaxoSmithKline) and other invited experts facilitated the discussions.

Optimum Strategies for Preparing Figures for Publication was presented by **Eli Ney** and **Beth Mahler** of NIEHS. They explained how to make adjustments to photomicrographs using photoimaging software in a half-hour session for attendees.

Awards and Annual Business Meeting

On Wednesday evening, STP President **Gary Boorman** welcomed attendees to the Awards Ceremony followed by the Annual Business Meeting. The slides from the Awards presentation and business meeting are posted on the Committee page of the Web site. He recognized the Student Travel Award Winners and the Young Investigator winners (See page 10). **Sandra Eldridge** (Charles River), **Robert Sills** (NIEHS), and **George Parker** (Biotechnics Inc.) received plaques as the winners of the Member-Get-A-Member Award for recruiting the most new members.

Ricardo Ochoa presented the Achievement Award to **Dr. Robert Maronpot** (See page 7) **Dr. Boorman** thanked **Susan Elmore** for organizing another excellent NTP Symposium. **Dr. Boorman** presented

continued on page 7

San Francisco

continued from page 6

plaques and thanked the following outgoing committee chairs and Executive Committee members for their service: **Ken Shafer** (Vet Path Services, Inc.), Scientific and Regulatory Policy Committee (SRPC); **Eugenia Floyd** (Pfizer, Inc), Symposium Scientific Chair; **Denny Frost** (Covance), Internet Committee; Peter Mann (EPL, Inc.) Global Editorial and Steering Committee (GESC); **Gerald Long** (Past President); **Jeff Engelhardt** (Secretary-Treasurer); and **Jerrold Ward** (Councilor). **Rogely Boyce** (Beechy Ridge ToxPath) accepted the *Journal* Best Paper Award (see page 10) for Novel Vascular Lesions in Mice Given a Non-Peptide Vitronectin Receptor Antagonist.

Kathleen Funk (EPL, Inc.) and **Jerrold Ward** (Consultant) gave a presentation about Washington, DC, the location for the 28th Annual Meeting. The meeting will be held June 21–24, 2009, at the Marriott Wardman Park Hotel.

The Presidents Reception was held on Wednesday evening in the Atrium Lobby of the Hyatt Regency. Two sponsored receptions were hosted during the week for all attendees. Charles River held a reception Saturday evening and EPL, Inc. held their reception on Monday evening.

ACHIEVEMENT AWARD

Robert R. Maronpot with President Ricardo Ochoa

Dr. Robert R. Maronpot was honored as the 2008 Achievement Award Recipient at the 27th STP Annual Meeting Award Ceremony on June 25 in San Francisco. Incoming President **Ricardo Ochoa** presented the award.

He said that Dr. Maronpot had significantly influenced the field of Toxicologic Pathology in many different ways, including as a leader, manager, educator, and author and that he is internationally recognized and highly respected for his scientific contributions to toxicologic pathology and the advancement of STP. Dr. Maronpot served as President of STP in 2001 and as Editor-in-Chief of its journal, *Toxicologic Pathology,* from 2001–2004. Dr. Maronpot received his Doctorate of Veterinary Medicine in 1965 from Michigan State University, an M.S. in nutritional pathology from Michigan State University in 1966, and an M.P.H. from Harvard University in 1972. He has worked more than 40 years in experimental pathology with emphasis on animal models of carcinogenesis.

He serves on several journal editorial boards. In addition to over 250 peer-reviewed publications, he has edited a comprehensive text entitled *Pathology* of the *Mouse* (1999), co-edited a book entitled *Pathology of Genetically Engineered Mice* (2000), and has several years of experience in application of imaging technologies, especially MRI, to toxicologic pathology.

In 2007 he retired from the National Institute of Environmental Health Sciences (NIH) and the National Toxicology Program where he was Chief, Laboratory of Experimental Pathology. As a leader and manager, he started at NIEHS as part of a very small, fledging program of experimental pathology in 1981. During his appointment, his vision of increasing the impact of the pathologist in toxicology through a wider use of scientific tools was so successful that, by the end of his tenure, that program had expanded to 50 people, all dedicated to the elucidation of scientific issues in pathology. The pathologists on the current staff at NIEHS joined the program during his tenure and constitute a remarkable group of scientists. As an educator, Dr. Maronpot also created the training program at NIEHS, where many toxicologic pathologists have been trained through the years. The program maintains two to three trainees, therefore creating a scholarly learning environment. He was the originator of the NTP Symposium held in conjunction with the STP Symposium that has always been well-received and considered an important component of the meeting. Dr. Maronpot also has adjunct faculty appointments at Duke University, North Carolina State University and the University of North Carolina. In addition to his leadership role as editor of the *Pathology of the Mouse,* which is a seminal publication to all toxicologic pathologists, he was instrumental in organizing some of the first panels of pathologists to achieve better standardization of our terminology. Specifically impactful was his leadership in the definition of liver proliferative lesions as well as his role in the nomenclature of lesions of the forestomach. These early efforts set the tone for the achievement of consensus in the field, and have been critical to the later achievement of clarity in our communication of risk assessment. Dr. Maronpot also contributed significantly to the use of *in vivo* imaging, particularly MRI and its use in the study of the development, progression and regression of proliferative changes in rodents.

Dr. Maronpot continues to advance the profession by working as a consultant and striving to address some of the issues of consistency between pathologists. He expert advice is frequently sought on numerous National and International Committees, Working Groups, and Task Forces. He serves as an example to the present and future membership for his scientific achievements and selfless dedication to the profession.

San Francisco

27th Annual Meeting EXHIBITORS

Abaxis, Inc.

Ani Lytics, Inc.

Antech Diagnostics GLP

Aperio

AstraZeneca

Bench International

BioImagene, Inc.

Carl Zeiss MicroImaging, Inc.

CIT

CompuCyte Corporation

Department of Defense Veterinary Pathology Residency

DMetrix, Inc.

EPL Archives, Inc.

EPL, Inc.

Faxitron X-Ray, LLC

HSRL (Histo-Scientific Research Laboratories)

Histotox Labs, Inc.

Huntingdon Life Sciences

Instem

Labcat

LifeSpan BioSciences

Marshall BioResources

Metabolon, Inc.

Milestone Medical

National Toxicology Program (NTP)

Olympus America, Inc.

Pacific BioLabs

PDS Preclinical Data Systems, Inc.

Pfizer Global Research and Development

Poly Scientific R&D Corp.

Premier Laboratory, LLC

Roche

SAGE Publications

Saunders/Mosby

SNBL USA, Ltd.

The Society of Toxicologic Pathology

Systems Pathology Company, LLC

Triangle Biomedical Sciences, Inc.

Ventana Medical Systems, Inc.

Xybion Medical Systems

BEST PAPER AWARD

Novel Vascular Lesions in Mice Given a Non-Peptide Vitronectin Receptor Antagonist

Volume 35, Number 7 of ***Toxicologic Pathology***

Sabine Rehm[1], Roberta A. Thomas[1], Kim S. Smith[1], Rosanna C. Mirabile[1], Tracy L. Gales[1] Scot L. Eustis[2], and Rogely W. Boyce[1]

1. GlaxoSmithKline, King of Prussia, PA, United States
2. Las Vegas, NV, United States

YOUNG INVESTIGATOR AWARD WINNERS

First Place

Tzuyin (Cindy) Lin

The Ohio State University

The Novel HSP90 Inhibitor STA-9090 Exhibits Activity Against KIT Dependent and Independent Malignant Mast Cell Tumors

Second Place

Alok Sharma

Covance

Kainic acid Induced F-344 Rat model of Mesial Temporal Lobe Epilepsy: Gene Expression and Canonical Pathways

Third Place

Shankang Ma

University of Louisville

Regression of Fibrosis by a Simple Plasmid-Mediated Metallothionein Gene Therapy in Mice

STUDENT TRAVEL AWARDS

Shankang Ma

University of Louisville

Kara Corps

Michigan State University

Janet Beeler-Marfisi

University of Ontario-Guelph

Danielle Brown

North Carolina State University

Mariko Matsui

University of New Caledonia

Brent Walling

University of Illinois

Tania Carvalho

IPOFG/Portugal

Sanvidhan Suke

University of Delhi, India

Yuval Ramot

Hebrew University Israel

Sunish Mohanan

Wake Forest University

STP THANKS ITS EVENT SPONSORS FOR THEIR GENEROUS CONTRIBUTIONS TO THE SAN FRANCISCO MEETING

Reception Sponsors

Charles River—*Saturday Evening*

EPL, Inc.—*Monday Evening*

Continental Breakfast Sponsors

Genentech Preclinical Safety Assessment—*Monday Morning*

Roche—*Tuesday Morning*

San Francisco

STP Sponsors

The Society of Toxicologic Pathology thanks the following sponsors for their generous contributions:

Diamond:

AstraZeneca

Pfizer, Inc.

Emerald:

Boehringer-Ingelheim Pharmaceuticals, Inc.

GlaxoSmithKline

Wyeth

Ruby:

Allergan

Amgen

Biogen Idec

Bristol-Myers Squibb

Covance

Genentech, Inc.

Huntingdon Life Sciences

MPI Research Inc.

Novartis Pharmaceuticals Corporation

Roche

Schering-Plough Research Institute

Society of Toxicology

Vet Path Services, Inc.

Sapphire:

Ani Lytics, Inc.

Baxter Healthcare Corporation

Daiichi Sankyo Co., Ltd.

Dow AgroSciences

Eli Lilly and Company

EPL, Inc.

GEMpath Inc.

Merck Research Laboratories

sanofi-aventis

Seventh Wave Laboratories LLC

TAP Pharmaceutical Products, Inc.

WIL-Biotechnics

Pearl:

Aperio

Applied Veterinary Pathobiology, PLLC

Charles River

David G. Fairchild, DVM, Inc.

HSRL (Histo-Scientific Research Laboratories)

Millennium Pharmaceuticals, Inc.

Contributing:

Colin Rousseaux and Associates

Thank you for your support!

STP Headquarters:
1821 Michael Faraday Drive, Suite 300,
Reston, VA 20190
Tel: (703) 438-7508 Fax: (703) 438-3113
Web site: www.toxpath.org

MEMBER SPOTLIGHT

INTERVIEW WITH MAURICE CARY

By Frank Simutis

Q. *Where do you work and what are your main job responsibilities?*

A. I am the CEO of Pathology Experts LLC, an international pathology/toxicology/preclinical consulting firm specializing in problem-solving peer and report reviews, troubleshooting regulatory issues and documentation preparation, placing/monitoring of studies in CROs globally, and qualification (scientific, animal health, GLP) inspections of CROs anywhere in the world. Our business office is in Rye, New York. I handle my CEO responsibilities from our office in Binningen, Switzerland, which is just on the outskirts of Basel. The company consists of only senior level experts (20 years + experience), so I spend most of my time coordinating the scientific activities of the company, while expanding our expertise base.

Q. *Where did you receive your veterinary and pathology training?*

A. I received my DVM from Tuskegee University. I trained in pathology at Washington State University (WSU), where I received my Ph.D. while also doing a residency at the Washington Animal Disease Diagnostic Laboratory.

Q. *What aspects of your current position (or your career, for that matter) Do you find most rewarding?*

A. I have enjoyed all aspects of my career, which has allowed me to explore many of nature's fascinating mysteries while working for society and the greater public good. I especially enjoy my role now as CEO of Pathology Experts LLC after going on 23 years of experience in industry. This role allows me to pull all of my training and experience together and to use them in a broad-based mechanistic approach to preclinical safety and drug development. This approach was not always possible. It was not so in 1985 when I started in industry. I am happy to say, that now since more and more companies are moving toward understanding the underlying causes of a particular finding and tying that in with other findings in a "weight of the evidence" approach to risk assessment, working at this level in industry is now extremely rewarding intellectually. Specifically, within the company we have some of the top people on the planet and I love working with them to deliver the highest level of expertise and the most robust evaluations to enable our clients to make the best decisions possible. This hopefully translates to the overall public good, and that is especially rewarding.

Q. *Did you foresee your present career when you started your pathology training?*

A. No, I did not see my present career at all when I started training to be a pathologist.

Q. *What or who "sparked" your interest in pathology?*

A. My interest in pathology was sparked by my first professors in pathology at Tuskegee. They were Drs. T. Graham, W.O. Jones, and A. Dade. I was fascinated and inspired by their intellect and their level of command of the most intricate details. I realized in my first day in my first pathology course, this was where I wanted to focus professionally.

I must say that somehow I was always fascinated with pathology, long before I knew there was such a science. This takes me back to childhood growing up in Washington, D.C., where my favorite museum as a 9 year old was the Smithsonian Medical Museum in the old red brick building down on the mall. I was fascinated by all the specimens, which of course horrified all my friends and cousins!

Q. *Do any aspects of your pathology training seem uniquely suited for your current career?*

A. In industry one must tie together data and scientific aspects from various disciplines, many of which in a typical pharmaceutical company lie outside of the pathology department. In training as a pathologist, one must learn many different scientific disciplines and have a pretty good handle on them in order to be a good pathologist. I think the need to obtain a certain level of competency in so many areas, has prepared me extremely well to handle the multi-disciplinary approach to drug development in today's world. At WSU they hammered mechanisms, biochemistry, immunopathology, writing/presentation of results, diagnostic skills, and a bunch of other stuff into our heads, that continues to serve me extremely well to this day. They really prepared us (amazingly so in my opinion) for the unique demands in the current world of drug development.

Q. *Where might you see the field of toxicologic pathology headed in the next 5 to 10 years?*

A. I believe it will continue to move toward understanding the underlying molecular mechanisms of findings and tying that in with what we see morphologically. I also believe that we will rapidly move toward the use of advanced digital imaging technology as the need for expert level input increases globally, particularly when we consider the aging of the profession and the shrinking of the expertise pool.

Q. *Who are your family members?*

A. I live in Switzerland with my Lebenspartnerin and have 4 children. My oldest son from a previous relationship is 24 and lives in Tacoma, Washington. I am extremely lucky to have been blessed with young children at a later age in life, so there is an age gap between my oldest child and my three younger ones. The three younger children live with me in Switzerland and their ages are 5, 3 and 1.

continued on page 13

Continued from page 13

Q. *What are your hobbies/interests?*

A. When I am not working, I spend my private time with my family. With young kids I spend quite a bit of time at the playground and kid's stuff like that. I love it! My kids could care less about my work and standing in the profession. They just want to get on the swings, the slide, or go to the swimming pool! They are my main interest.

Beyond that, I like to go to the gym and workout. I also like bicycling, swimming, and rollerblading. I love going to the beach, which is a little difficult to do in Switzerland, but we try to go to the beach as much as we can. Oh yes, and of course I like to ski. I love reading non-fiction and biographies. And I love watching movies.

Q. *Just for fun, is there something you would like to mention to the member community that they would be surprised to know about you?*

A. I am an extremely private person, so once I am out of my professional circle I am desperately trying to find some time and space to be alone or to be with my family or a close friend or two. I love to be alone, to sit somewhere and just think. I also believe that most people don't realize how introverted I am. It takes a lot for me to move around at meetings and talk with a bunch of people. I am basically an introvert that has learned to be somewhat extroverted. So I really don't like a lot of attention and I don't like to be in the middle for everyone to see. I am most happy to be in the background.

THE WRINKLED SECTION

Lightening the Load

by James W. Crissman

Writing the Wrinkled Section has never required that I be anything but myself. Mining the human experience for what relates, however loosely, to our common endeavor and finding the humor in it is what I do anyway. I've always been the smart ass in the back of the class. Having this column so that I can crack wise to a larger audience is ice cream for my ego. Going for the laugh has always been worth it: it gets me in trouble, and it gets me through it.

But my funny bone was stunned when I learned just before our big meeting in San Francisco that I had an almost certainly malignant mass on my right kidney. They don't biopsy these; they just get them out. As of this writing I've had to wait a month for surgery—it finally comes out tomorrow. There isn't much that's funny about this, and for the first week after getting the news I was shocked, depressed, and afraid. We caught it early on a CT scan done for another very minor reason, and I will probably be okay, but there was research to do, consultations and second opinions to get; pre-op blood work, chest x-rays, and an EKG to collect; a rush to meet deadlines before the end of work today, and a dozen fun things to cancel. My summer has spun down the toilet with cancer at the center of the vortex.

So the slow return of the good humor man has been welcome over the last weeks. I can't say it's a surprise; it's always been the best defense I have against the slings and arrows of outrageous fortune, not to mention the daily dings we all endure. And of course friends can be even better friends if you put them at ease with a laugh.

So here are a few of my lighter thoughts, cherished friends: Lance became unbeatable, winning the Tour de France seven times after becoming, as Robin Williams dubbed him, The Uniballer. Kidneys weigh at least four times what testicles do (more in my case) so I figure I'll be dusting my old buds on my beloved two-wheelers. They'll all be looking to jettison their redundant organs. I also figure that with one kidney I'll only get half as pissed off, or pissed off only half as often, at the ignorance and injustice in the world. However, on this point I have been reminded that the remaining kidney will compensate, and that this, after all, is an election year. Still, it's been a good kidney up till now, producing its share of 80,000 gallons of urine over the last 57 years—that's roughly the equivalent of a public swimming pool.

So glasses were raised to the lumpy old bugger. Last evening after the forty-mile Tuesday night road ride and hammerfest, we took him out to filter his last beer—Bell's Oberon, a fine summer brew. I get no alcohol for twenty-four hours before the gas, so technically I could have continued drinking until noon today, but somehow resisted. None-theless, tonight, on the sober eve of ectomy, we're going to the woods to bounce the bloody old red bean over his last thirteen miles of log piles, rocks, roots, and dirt singletrack. We'll roll like there's no tomorrow. He'll never see the punch line coming.

P.S.: The pathology report was as good as it could be. I'm going to be okay. Thanks for all your good wishes.

UPCOMING MEETINGS

September 14–16, 2008
Fourth RTP Rodent Pathology Course—Immunopathology
Research Triangle Park, NC
http://continuingeducation.ncsu.edu/rodentpath/

September 21–26, 2008
6th European Congress of Toxicologic Pathology (Joint ETS/ESTP Meeting)
Edinburgh, Scotland
www.eurotoxpath.org/meetings

September 22–25, 2008
SPS 8th Annual Meeting
Monana Terrace Convention Center
Madison, WI
www.safetypharmacology.org

October 23–25, 2008
Second Conference of the Society for Toxicologic Pathology in India
Hotel Atria, Bangalore, India
www.toxpathindia.com

November 13–14, 2008
23rd Annual Meeting of the British Society of Toxicological Pathologists
London, England
www.bstp.org.uk

November 9–12, 2008
ACT Annual Meeting
Hilton El Conquistador
Tucson, AZ
www.actox.org

November 15–19, 2008
ACVP Annual Meeting
Hilton Palaciodel Rio Hotel
San Antonio, TX
www.acvp.org

December 4–5, 2008
Hemangiosarcoma in Rodents:Mode-of-Action Evaluation and Human Relevance, Hosted by SOT and sponsored by STP.
Westin Arlington Gateway Hotel, Arlington, VA
http://www.toxicology.org/ai/meet/hr-COF_meeting.asp

March 15–19, 2009
SOT 48th Annual Meeting
Baltimore, Maryland
http://www.toxicology.org/AI/MEET/AM2009/index.asp

June 20, 2009
NTP Symposium
Wardman Park Hotel
Washington, DC
www.toxpath.org/AM2009/index.asp

July 21–25, 2009
8th Toxicology & Pathology in Drug Discovery & Development Short Course, Co-sponsored by the Society of Toxicologic Pathology.
Limited enrollment: To be placed on the waiting list and receive conference mailings, send a message to: E-mail: ope@cvm.uiuc.edu
University of Illinois at Urbana-Champaign
Champaign-Urbana, IL
www.cvm.uiuc.edu/ope/itp